Pharma BD Deal Intelligence
Bayer agreed to acquire San Diego-based Vividion for $1.5B upfront plus up to $500M in milestone payments (~$2B total). Vividion's chemoproteomics platform targets historically undruggable proteins including cancer- and inflammation-related transcription factors. Closed August 19, 2021. Post-close update (as of June 2026): Vividion has operated as an independent, wholly-owned Bayer subsidiary and the platform thesis is materially validated - it has advanced multiple chemoproteomics-derived programs into the clinic, including a Phase I oral STAT3 inhibitor (VVD-130850, dosing started Feb 2024), a Phase I oral RAS-PI3Ka inhibitor (VVD-159642 / NCT06804824, first patient dosed Apr 2025), and in June 2025 secured exclusive worldwide rights to clinical-stage covalent WRN inhibitor VVD-214 (RO7589831) from its 2020 Roche collaboration.